Lilly’s ulcerative colitis therapy mirikizumab finally snags FDA approval

The FDA on Thursday approved Eli Lilly’s first-in-class antibody mirikizumab for the treatment for adults with moderately to severely active ulcerative colitis. Mirikizumab, which will be sold under the brand name Omvoh, joins a crowded inflammatory bowel disease market.